Optimization · Research guide

Track your dog's bloodwork without chasing every red flag

Why a personal trend can be useful, how collection context changes interpretation, and where biomarker enthusiasm can get ahead of clinical value.

The takeaway

Nara’s take.

Bloodwork becomes more informative when results are connected to your dog's history and the conditions of collection. A number moving is a reason to interpret—not automatically a diagnosis, a treatment target or proof of better ageing.

How it may work

Your dog's previous result is useful context

Laboratory reference intervals describe a population. Individual dogs also have their own patterns, and biological variation means a single result can move without representing a new disease.

A longitudinal study of apparently healthy Golden Retrievers examined variation between annual wellness visits. It helps explain why a trend can sometimes be informative even when values remain inside the laboratory interval—and why not every movement deserves alarm.

Sources: [1]

What the research shows

Detection is not the same as proven outcome benefit

Repeated screening and renal-health studies in apparently healthy ageing dogs show the potential to detect new findings over time. That is a good reason to preserve prior results and review them together.

These studies do not establish that frequent testing of every healthy dog extends lifespan. Nor does a marker associated with disease prove that forcing the marker toward a preferred number improves the outcome. A useful monitoring plan connects a measurement to a clinical question and a possible action.

Sources: [2], [3]

Nara's interpretation

Collection context belongs beside the value

Nara would keep fasting status, recent activity, illness, medicines, supplements, units and the laboratory's own interval beside each report. Comparisons become less reliable when those details disappear.

Creatine supplementation is one concrete example: canine feeding research measured changes in circulating creatinine after a creatine-containing combination. That does not establish kidney damage, but it also does not make an abnormal result safe to ignore. The clinician needs the whole context.

Evidence informing this guidance: [1], [4]

Nara's practical guidance

What this means for your dog

Nara suggests retaining original reports, checking that units and reference intervals travelled with the data, and agreeing which changes merit a repeat or investigation. Where feasible, comparable collection conditions make a trend easier to read.

Testing has costs beyond the blood draw: false alarms, follow-up procedures and decisions based on noise. More frequent is not automatically better. Use your veterinary team's plan for age, disease and risk, and do not delay care for symptoms because an earlier panel was normal. Nara can organize the record; it cannot make a biomarker equivalent to a diagnosis.

Evidence informing this guidance: [1], [2], [3]

Follow the evidence

Sources and review notes.

Primary studies, clinical guidance and explicitly labelled sponsor disclosures. A mechanism, an observational association and a treatment result are different kinds of evidence.

Editorial research update: 2026-09-24. These guides build on Nara’s existing source records and a fresh check of accessible primary abstracts, full texts and official pages. This is not an exhaustive systematic review or a new independent clinical review. The evidence assessment retains its own date and status. Practical examples are Nara’s interpretation, not validated treatment protocols.

[1] 2021 · dog · longitudinal biochemical-variation study
Variation in biochemistry test results between annual wellness visits in apparently healthy Golden Retrievers
Jeffery U et al.. Journal of Veterinary Internal Medicine.
10.1111/jvim.16021
Supports within-dog longitudinal interpretation and reference-change concepts.
[2] 2025 · dog · prospective longitudinal screening study
Exploring the Importance of Repeated Health Screening in Healthy Older Dogs
Marynissen S et al.. Journal of Veterinary Internal Medicine.
10.1111/jvim.70166
Demonstrates detection value of repeated health screening without proving that screening frequency improves final health outcomes.
[3] 2025 · dog · prospective longitudinal renal-screening study
Longitudinal Study of Renal Health Screening in Apparently Healthy Aging Dogs
Marynissen S et al.. Journal of Veterinary Internal Medicine.
10.1111/jvim.70116
Shows longitudinal renal-marker and CKD-detection value in apparently healthy aging dogs.
[4] 2022 · dog · small crossover feeding pharmacokinetic/biomarker study
Addition of a combination of creatine, carnitine, and choline to a commercial diet increases postprandial plasma creatine and creatinine concentrations in adult dogs
Banton S, Braun U, Squires EJ, Shoveller AK. Frontiers in Veterinary Science.
10.3389/fvets.2022.1063169
Shows circulating creatine and creatinine effects; does not establish canine functional efficacy.

Keep reading

Connected questions.

Preventive care

Screening cadence, early detection, and baseline diagnostics before decline is visible.

Creatine

Cellular energy buffering and muscle performance, largely untested in dogs.

Nutrition

Diet completeness, calorie accuracy, and feeding pattern — the substrate everything else sits on.

Open Nara’s evidence assessment

The guide above explains the topic. This separate record preserves the accepted claim, confidence, limitations and safety context. Publishing an article does not upgrade the science or turn an experimental intervention into a recommendation.

Nara’s evidence view

Veterinary or clinical context

SupportedCanine lifespan outcomesModerate confidence

The claim we’re evaluating

Serial biomarkers and repeated health screening can provide useful within-dog longitudinal information and can identify previously unrecognized disease or mortality-associated signals, but evidence does not show that increasing testing frequency itself improves canine healthspan or lifespan.

Nara’s interpretation

Canine biomarkers can provide useful longitudinal context, particularly when change within the same dog is interpreted alongside analytical and biological variability. Prospective screening studies show that repeated evaluation can uncover previously unrecognized disease, and Dog Aging Project metabolomics has identified blood measures associated with subsequent mortality. Those findings do not establish that testing more frequently, by itself, improves morbidity, healthspan, or lifespan; proving that claim would require outcome-focused comparisons of screening strategies.

This is an umbrella assessment. The evidence differs materially depending on the outcome and the specific form of the intervention, so Nara evaluates those narrower claims separately.

How we reached this view

What the evidence shows

Annual laboratory data from apparently healthy Golden Retrievers demonstrate that individual dogs can have meaningful year-to-year biochemical variation and support use of within-dog change intervals in interpretation. Prospective longitudinal screening of apparently healthy older dogs identified previously unrecognized systemic disease at baseline and additional clinically relevant findings during follow-up, including renal disease detection. Dog Aging Project analysis of 937 companion dogs used longitudinal survival models on 133 plasma metabolites and found approximately 17% associated with mortality, with 23 meeting a false-discovery-rate threshold below 5%. These studies establish longitudinal information and risk-association value, not a causal benefit from testing frequency. No randomized or pragmatic canine trial was identified showing that more frequent biomarker testing itself improves quality of life, morbidity, healthspan, or survival.

Important limitations

Detection studies do not compare testing frequencies in randomized groups and therefore cannot establish that more testing improves outcomes.
A biomarker's association with mortality or disease does not establish that modifying that biomarker modifies risk.
Repeated screening can identify abnormalities without proving that earlier intervention based on those abnormalities improves the final clinical outcome.
Potential downstream effects of false-positive or incidental findings are not captured by most biomarker-discovery studies.

What would change Nara’s view

What would strengthen our view

Randomized or pragmatic canine trials comparing defined screening intervals or strategies and measuring morbidity, quality of life, major clinical events, or survival.
Evidence that interventions triggered by defined longitudinal biomarker changes improve clinically meaningful outcomes compared with usual care.

What could weaken our view

Screening-strategy trials showing no health benefit despite substantially greater testing intensity.
Evidence that extra screening produces material false-positive, overdiagnosis, procedural, or treatment harms without compensating clinical benefit.

What could change our position

Demonstrated improvement in canine health outcomes from a defined screening strategy could support a stronger claim about that specific strategy while remaining distinct from generic 'more testing is better' language.
Evidence of net harm from intensive screening could move specific testing strategies toward potential_concern.
Mortality-associated biomarkers alone would not change Nara's position to an intervention claim without evidence that acting on them improves outcomes.

Safety and clinical context

A biomarker outside a reference interval is not by itself a diagnosis.
A biomarker changing after a diet, supplement, medication, activity, or other intervention establishes temporal association, not causation.
A biomarker moving in a statistically or directionally favorable way is not automatically evidence of improved healthspan or lifespan.
Clinical laboratory testing and interpretation of potentially pathological abnormalities inherently involve veterinary context.

Evidence record

Nara position: Veterinary or clinical context
Evidence maturity: Supported
Most direct relevant evidence: Canine lifespan outcomes
Overall confidence: Moderate confidence
Evidence reviewed through: 2026-08-12
Assessment date: 2026-08-12
Review status: Initial Nara internal evidence assessment
Framework: Nara Evidence Framework v1.0

How Nara evaluates science

Anchor sources

Variation in biochemistry test results between annual wellness visits in apparently healthy Golden Retrievers

Journal of Veterinary Internal Medicine · 2021 · dog

longitudinal biochemical-variation study

Supports within-dog longitudinal interpretation and reference-change concepts.

10.1111/jvim.16021

Exploring the Importance of Repeated Health Screening in Healthy Older Dogs

Journal of Veterinary Internal Medicine · 2025 · dog

prospective longitudinal screening study

Demonstrates detection value of repeated health screening without proving that screening frequency improves final health outcomes.

10.1111/jvim.70166

Longitudinal Study of Renal Health Screening in Apparently Healthy Aging Dogs

Journal of Veterinary Internal Medicine · 2025 · dog

prospective longitudinal renal-screening study

Shows longitudinal renal-marker and CKD-detection value in apparently healthy aging dogs.

10.1111/jvim.70116

Dogs and humans share biomarkers of mortality

The Journals of Gerontology: Series A · 2025 online / 2026 issue · dog

longitudinal companion-dog metabolomics survival study

Direct canine mortality-associated biomarker evidence; observational and not evidence that testing or changing a biomarker improves survival.

10.1093/gerona/glaf279

Your dog’s context

Bring this back to your dog.

Loading your dog’s context…